Inflammatory Breast Carcinoma (IBC) - Management

Overview

Inflammatory breast carcinoma: erythema, peau d'orange, nipple retraction, and satellite skin nodules. (Schwartz's Principles of Surgery, 11e, Fig. 17-39)

Diagnosis and Staging

• Erythema and/or edema (peau d'orange) covering at least one-third of the breast
• Acute onset within 6 months
• No unique histologic subtype required - it is a clinical diagnosis

Dermal lymphatic tumor emboli on skin punch biopsy - the pathologic hallmark of IBC (H&E, 40x). Current Surgical Therapy, 14e, Fig. 3

• 85% have regional lymph node involvement
• 25-30% have distant metastases at presentation
• No discrete central breast mass in ~50% of patients on imaging

• Bilateral diagnostic mammogram + targeted ultrasound
• Core needle biopsy of any breast mass + skin punch biopsy
• Breast MRI if imaging is equivocal or mammogram/US non-diagnostic
• PET-CT to rule out concurrent metastatic disease (strongly recommended)
• Receptor testing: ER, PR, HER2 status
• Genetic testing for hereditary risk assessment

IBC vs. Non-IBC Locally Advanced Breast Cancer

Treatment: The Multimodal Standard

Step 1 - Neoadjuvant Systemic Therapy (Primary Treatment)

• Anthracycline + taxane-based regimens are preferred
• Neoadjuvant chemotherapy produces dramatic regression in up to 75% of cases
• Patients who fail to respond or progress may be offered additional systemic therapy and/or preoperative radiation

• HER2+ disease: Add trastuzumab ± pertuzumab to the chemotherapy backbone
• HR+ (ER+/PR+) disease: Endocrine therapy is initiated postoperatively (not substituted for chemotherapy)
• Triple-negative IBC: Standard anthracycline-taxane backbone; immunotherapy/PARP inhibitors per trial/guideline eligibility

Step 2 - Surgery (After Documented Response)

• Breast-conserving surgery is absolutely contraindicated - the widespread dermal lymphatic involvement precludes margin-negative resection
• Sentinel lymph node biopsy (SLNB) is absolutely contraindicated - MRM with obligatory ipsilateral level I/II axillary lymph node dissection (ALND) is required regardless of response to neoadjuvant therapy
• Level III dissection may be added if gross disease persists in the level II/III space
• Immediate breast reconstruction should be avoided (or done in a delayed fashion) because postmastectomy radiation is always required and immediate reconstruction complicates delivery and increases complications

Step 3 - Postmastectomy Radiation Therapy (PMRT)

• Target fields: Chest wall + ipsilateral axilla + infraclavicular + supraclavicular + internal mammary lymph node basins
• Dose: 50-60 Gy over 4-6 weeks

Step 4 - Adjuvant Systemic Therapy

• Complete the planned chemotherapy regimen if not fully administered preoperatively
• HER2+ disease: Complete up to 1 year of HER2-targeted therapy (can be given concurrently with radiation and endocrine therapy)
• HR+ disease: Initiate endocrine therapy (aromatase inhibitor or tamoxifen per menopausal status)
• Patients with residual disease after neoadjuvant therapy may benefit from additional agents (e.g., capecitabine in TNBC, neratinib in HER2+) per current guidelines

Prognosis

• 5-year survival approaches ~30-41% with the complete trimodality approach
• Pathologic complete response (pCR) to neoadjuvant therapy is the strongest favorable prognostic factor
• Disease-free and overall survival are significantly improved when pCR is achieved

Summary Algorithm (Non-Metastatic IBC)

Diagnosis (clinical + biopsy + receptor status + PET-CT staging)
        ↓
Neoadjuvant systemic therapy
(Anthracycline + taxane ± trastuzumab/pertuzumab [HER2+])
        ↓
Assess response (clinical ± imaging)
        ↓
Modified Radical Mastectomy + ALND (mandatory)
        ↓
Postmastectomy Radiation (chest wall + all regional nodal basins)
        ↓
Complete adjuvant systemic therapy + endocrine therapy (if HR+)
        + 1 year HER2-targeted therapy (if HER2+)

Recent Evidence